FindTrial
Sign In

THE IMPORTANCE OF ANTIMULLERIAN HORMONE IN DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME

ANTI-MULLERIAN HORMONE LEVEL FOR THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/02/007800
Enrollment
280
Registered
2017-02-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients attending the endocrine clinic for menstrual irregularities, hyperandrogenism or infertility

Interventions

None listed

Sponsors

Sanjay Gandhi Postgraduate Institute of medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients attending the endocrine clinic for menstrual irregularities, hyperandrogenism or infertility were recruited

Exclusion criteria

Exclusion criteria: Age Patients with other causes like hypergonadotrophic hypogonadism, hypogonadism due to pituitary lesion, 21-hydroxylase-deficient nonclassic adrenal hyperplasia, Thyroid dysfunction, Hyperprolactinemia, Neoplastic androgen secretion, Drug induced androgen excess, Cushingâ??s syndrome

Design outcomes

Primary

MeasureTime frame
1.To calculate diagnostic power of serum AMH levels in diagnosis of PCOS 2) To assess relationship between Polycystic Ovarian Morphology and AMH levels.Timepoint: Final outcome will be assessed at April 2017—

Secondary

MeasureTime frame
To assess whether AMH level can replace ultrasound in diagnosis of PCOSTimepoint: Will be assessed at April 2017—

Countries

India

Contacts

Public ContactDr Preeti Dabadghao

Sanjay Gandhi Post-Graduate Institute of Medical Sciences(SGPGIMS)

preetidab@gmail.com05222494371

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026